News stories about Paratek Pharmaceuticals (NASDAQ:PRTK) have been trending somewhat positive recently, according to Accern Sentiment. The research group scores the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Paratek Pharmaceuticals earned a coverage optimism score of 0.21 on Accern’s scale. Accern also assigned news coverage about the specialty pharmaceutical company an impact score of 47.1744795057436 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
PRTK has been the topic of several recent analyst reports. Zacks Investment Research raised shares of Paratek Pharmaceuticals from a “hold” rating to a “buy” rating and set a $18.00 price objective on the stock in a research report on Tuesday, January 23rd. BidaskClub downgraded shares of Paratek Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, December 2nd. Cantor Fitzgerald set a $50.00 price target on shares of Paratek Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, January 3rd. ValuEngine downgraded shares of Paratek Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, December 29th. Finally, HC Wainwright raised their price target on shares of Paratek Pharmaceuticals from $43.00 to $55.00 and gave the company a “buy” rating in a report on Friday, March 2nd. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $40.75.
Shares of Paratek Pharmaceuticals (NASDAQ:PRTK) traded down $0.10 during midday trading on Friday, hitting $14.40. 698,737 shares of the stock were exchanged, compared to its average volume of 349,001. The company has a debt-to-equity ratio of 0.72, a quick ratio of 9.56 and a current ratio of 9.56. The stock has a market cap of $447.80, a P/E ratio of -4.30 and a beta of 0.35. Paratek Pharmaceuticals has a 12-month low of $11.85 and a 12-month high of $29.00.
Paratek Pharmaceuticals (NASDAQ:PRTK) last announced its quarterly earnings results on Thursday, March 1st. The specialty pharmaceutical company reported ($0.78) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.03). The company had revenue of $5.07 million for the quarter, compared to analysts’ expectations of $5.00 million. Paratek Pharmaceuticals had a negative net margin of 706.00% and a negative return on equity of 93.16%. equities research analysts forecast that Paratek Pharmaceuticals will post -3.51 EPS for the current fiscal year.
In other news, Director Robert S. Radie sold 3,000 shares of the stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $14.22, for a total value of $42,660.00. Following the transaction, the director now owns 9,330 shares in the company, valued at approximately $132,672.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Adam Woodrow sold 14,333 shares of the stock in a transaction that occurred on Tuesday, February 6th. The stock was sold at an average price of $13.87, for a total transaction of $198,798.71. Following the completion of the transaction, the vice president now owns 62,367 shares in the company, valued at approximately $865,030.29. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 40,664 shares of company stock worth $573,226. Insiders own 4.90% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Paratek Pharmaceuticals (PRTK) Share Price” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at https://www.dispatchtribunal.com/2018/03/18/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-paratek-pharmaceuticals-prtk-share-price.html.
Paratek Pharmaceuticals Company Profile
Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.
Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.